Canadian from hantavirus-hit cruise ship tests positive
bbc - The individual is one of four former passengers on the MV Hondius isolating on Vancouver Island, British Columbia.
AI Summary: A Canadian passenger tested positive after an Andes‑virus outbreak aboard a cruise ship, and French authorities report the strain matches known South American viruses. Public health teams began targeted testing, contact tracing and onboard monitoring as experts debate what constitutes “close contact,” balancing realistic containment with the mild panic such exotic pathogens tend to inspire.
- Canada confirms hantavirus cases; testing and isolation underway (3)
- Defining close contact: contact‑tracing challenges and outbreaks at sea (3)
- Sequencing shows South American strain; ship arrival and WHO stance (4)
- All Other Stories
Canada confirms hantavirus cases; testing and isolation underway
Defining close contact: contact‑tracing challenges and outbreaks at sea
Sequencing shows South American strain; ship arrival and WHO stance
All Other Stories
Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds
medicalxpress - The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after symptom onset in the index patient, according to a Phase III randomized controlled trial published in the New England Journal of …
AI Summary: A randomized trial shows the oral antiviral ensitrelvir, used as post‑exposure prophylaxis, reduced the risk of symptomatic COVID‑19 in household contacts by roughly two‑thirds. The finding suggests a practical option for preventing spread after close exposure, offering public‑health teams a less dramatic but highly useful tool than lockdowns.
FDA clears 1st AI sepsis monitoring tool
Giles Bruce / beckershospitalreview - A tool from tech company Bayesian Health has become the first continuous AI sepsis monitor to gain FDA approval. The solution monitors hospital patients to detect deterioration and flag sepsis early on. The application was developed at Baltimore-based Joh…
AI Summary: Regulators have cleared the first AI‑driven sepsis early‑warning system for clinical deployment, enabling hospitals to use algorithmic alerts to identify patients at risk of deterioration earlier. The clearance opens the door for broader adoption of AI in acute care while renewing debates about clinical oversight, false alarms and integration into existing workflows.
What to know about new Ebola outbreak that has killed 65 people in Congo
medicalxpress - Africa's top public health body has confirmed a new Ebola outbreak in Congo's Ituri province, the 17th since the disease first emerged in the country in 1976.
AI Summary: Health authorities have confirmed a fresh Ebola outbreak in a remote province of the Democratic Republic of Congo that has killed roughly 65 people. Public-health teams are scrambling to trace contacts, ramp up surveillance, and deploy vaccines and treatments amid logistical and security hurdles. Containment hinges on rapid mobilization and local cooperation.
- Confirmed Ituri outbreak: cases, deaths and on-the-ground response (4)
- Vaccine shortages, high lethality and push for new vaccines (3)
- WHO declares global health emergency; international response underway (4)
- All Other Stories
Confirmed Ituri outbreak: cases, deaths and on-the-ground response
Vaccine shortages, high lethality and push for new vaccines
WHO declares global health emergency; international response underway
All Other Stories
Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
Cyril Erameh / nature - Nature Medicine, Published online: 15 May 2026; doi:10.1038/s41591-026-04402-wAn open-label, randomized controlled phase 2 trial comparing favipiravir with ribavirin for the treatment of mild-to-moderate Lassa fever in Nigeria found that favipiravir was s…
AI Summary: An open-label, randomized Phase 2 trial of favipiravir for Lassa fever reported encouraging results, suggesting antiviral benefit where few options exist. The study offers early clinical proof-of-concept, especially important for endemic West African settings, and calls for larger trials to confirm efficacy, optimize dosing, and assess deployment logistics.